EUNew treatments and approvals
New once-daily triple CFTR modulator approved in the EU for cystic fibrosis
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The European Commission has approved the combination vanzacaftor/tezacaftor/deutivacaftor for cystic fibrosis. This triple drug is taken once a day. The approval covers patients aged 6 years and older. Patients must have at least one non-class I mutation in the CFTR gene. In comparative studies, results for lung function were reported to be similar to the existing triple therapy. Better results were reported for the decrease in sweat chloride levels.
What does it mean for patients and families?
A new modulator option has become available in Europe for eligible patients. This drug is taken once a day. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
BioSpace (Vertex) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Cystic fibrosis
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.